←
Sharp Laboratory147 posts
Sharp Laboratory avatar

Sharp Laboratory

@Sharp_Lab

Assistant Professor @USFHealth, Cardiovascular Scientist, #Cardiometabolic Disease, #HeartFailure @ECI_ISHR HFpEFSummit.org

◷ Joined July 2023▧ 7 Photos and videos
Eric Topol avatar
⟳ Sharp Laboratory retweeted
Eric Topol@EricTopol·Nov 8

Semaglutide (Ozempic) improved left atrial and diastolic function in a randomized trial of patients with preserved ejection fraction heart failure (HFpEF) and obesity (via MRI) And achieved remission of symptoms in more than half of participants (2nd link) #AHA26 and @NatureMedicine nature.com/articles/s41591-0… nature.com/articles/s41591-0…

ZhenLi(Andrew) avatar
⟳ Sharp Laboratory retweeted
ZhenLi(Andrew)@andrewlizhen·Oct 20

Semaglutide, independent of weight loss, attenuates cardiac and hepatic remodelling in experimental heart failure with preserved ejection fraction academic.oup.com/eurheartj/a… Check out the latest research from @LeferLab

The Nobel Prize avatar
⟳ Sharp Laboratory retweeted
The Nobel Prize@NobelPrize·Oct 5

BREAKING NEWS The 2026 #NobelPrize in Physiology or Medicine has been awarded to Karl Deisseroth, Peter Hegemann and Georg Nagel “for their discoveries concerning light-gated ion channels and optogenetics.”

Post attachment
FatLiv_Lab avatar
⟳ Sharp Laboratory retweeted
FatLiv_Lab@FatlivL·Sep 30

Still in Milan 🇮🇹 and bringing the science! 🧪🔥Today, Dr. Cristina Rondinone presented our latest results at #EASD2026:🧬A novel unimolecular tetra-agonist targeting GLP-1, GIP, amylin & calcitonin receptors shows superior weight loss vs. tirzepatide or CagriSema in obese rats🐀

Post attachment
NEJM avatar
⟳ Sharp Laboratory retweeted
NEJM@NEJM·Sep 29

In the phase 3 TRIUMPH-1 trial involving patients with obesity, retatrutide, a triple hormone receptor agonist, resulted in substantial weight reduction and a decrease in knee osteoarthritis pain and obstructive sleep apnea events. Full trial results: nej.md/4ycgSHz

Post attachment
Sharp Laboratory avatar
Sharp Laboratory@Sharp_Lab·Jun 30

AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026) | Circulation ahajournals.org/doi/10.1161/…

Michael Morelli avatar
⟳ Sharp Laboratory retweeted
Michael Morelli@morellifit·May 21

I'm going through the retatrutide phase 3 data, and the cardiometabolic numbers are more interesting than the weight loss: - 24.1 cm off the waist on 12mg (9.5 inches) - significant drops in systolic blood pressure - triglycerides down - non-HDL cholesterol down - hsCRP down (a key marker of inflammation) I'm giving it a few years before people realize GLP-1s are more than just weight loss drugs.

This tweet is unavailable

Eric Topol avatar
⟳ Sharp Laboratory retweeted
Eric Topol@EricTopol·May 21

Retatrutide, a triple receptor drug for GLP-1, GIP, and glucagon, is the most powerful weight loss drug yet. A significant issue is too much weight loss among the trial participants. New randomized trial results announced today with 28% body weight loss. gift link nytimes.com/2026/05/21/scien…

Daniel J Drucker avatar
⟳ Sharp Laboratory retweeted
Daniel J Drucker@DanielJDrucker·May 12

In SURPASS CVOT tirzepatide was associated with a reduced risk of major kidney events driven by a reduction in new-onset macroalbuminuria in PPL with low-to-moderate-risk CKD #T2D and slowed decline in kidney function in high-risk chronic kidney disease. thelancet.com/journals/landi…

Eric Topol avatar
⟳ Sharp Laboratory retweeted
Eric Topol@EricTopol·Apr 23

In people with HFpEF (heart failure with preserved ejection fraction) and severe obesity, there is a heart muscle cell defect with sarcomere hyper-phosphorylation. Besides weight loss, sarcomere enhancers (not yet studied) may help. @ScienceMagazine science.org/doi/10.1126/scie…

Post attachment
Circulation avatar
⟳ Sharp Laboratory retweeted
Circulation@CircAHA·Apr 8

The rapidly evolving landscape of incretin-based therapies, including GLP1 agonists, necessitates rethinking trial design. Authors present challenges of placebo-controlled trials & potential ways to limit placebo exposure ahajrnls.org/4t0TrPa

Post attachment